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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground/Purpose: Extensively drug-resistant (XDR) Acinetobacter baumannii presents a
serious therapeutic and infection control challenge. This study aimed to explore the causes
for the rapid increase of XDR A. baumannii at a teaching hospital in Shanghai.
Methods: All consecutive clinical isolates of XDR A. baumannii were collected from January
to December 2010 at Huashan Hospital in Shanghai. The prevalence of carbapenemase genes
was investigated by polymerase chain reaction (PCR) amplification. Genetic relatedness
of the isolates was determined by enterobacterial repetitive intergenic consensus-PCR
and multilocus sequence typing. A retrospective caseecontrol study was performed for the
identification of risk factors of XDR A. baumannii infections.
Results: All 106 XDRA. baumannii isolates carried the blaOxA-23 gene andwere resistant to all anti-
microbial agents tested, except colistin, tigecycline and cefoperazone-sulbactam. One hundred
and five of the strains belonged to clonal complex 92 by multilocus sequence typing, and 78 were
classified as clone A1 by enterobacterial repetitive intergenic consensus-PCR. Intensive care unit
residency at the time of isolation, recent general anesthesia, the number of previous antibiotic
classes administered and previous hospitalization were identified as risk factors by case-control
study. Efficacy rates were 62.5% (5/8), 47.4% (9/19), and 42.9% (3/7) when the XDR patients were
treatedwith cefoperazoneesulbactam, carbapenems, or both cefoperazoneesulbactam and car-
bapenem, alone or in combination with other agents, respectively.Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, China.
u.cn (M. Wang).
.04.005
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102 Y. Li et al.Conclusion: XDR A. baumannii producing OXA-23 b-lactamase was clonally disseminated at a uni-
versity hospital in Shanghai. Cefoperazoneesulbactam and carbapenems alone or combined with
other antibiotics may benefit XDR A. baumannii infections in the absence of other effective anti-
biotics.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acinetobacter baumannii is notorious for its remarkable
ability to acquire antibiotic resistance and cause persistent
nosocomial infections.1,2 The propensity of A. baumannii to
be multidrug-resistant (MDR) or extensively drug-resistant
(XDR) presents therapeutic and infection control chal-
lenges. The problem is especially acute in China where
polymyxins remain unavailable and tigecycline only became
available in 2011. Invasive procedures such as mechanical
ventilation, intensive care unit (ICU) stay, recent surgery,
and use of broad-spectrum antibiotics are reported as risk
factors for colonization or infection by MDR A. baumannii.3
Due to the wide application of broad-spectrum antibiotics,
the resistance rates of A. baumannii to most classes of an-
tibiotics have continually increased during the past decades.
The emergence of carbapenem-resistant A. baumannii
(CRAB) has been described as the sentinel event of clini-
cally relevant antimicrobial resistance. The MYSTIC sur-
veillance program in 2008 demonstrated that 57.4% of A.
baumannii isolates were resistant to meropenem and 47.9%
resistant to imipenem in Europe.4 Among CRAB isolates, the
production of acquired carbapenem hydrolyzing class D b-
lactamases, including those belonging to the OXA-23, -24,
and -58 families, and overproduction of intrinsic class D b-
lactamase OXA-51 family are the most prevalent mecha-
nisms for carbapenem resistance.2 In China, surveillance by
the CHINET project showed that imipenem resistance rate
of A. baumannii increased from 30.1% in 2006 to 57.1% in
2010.5,6 Mirroring this national trend, the imipenem resis-
tance rate of A. baumannii at our hospital increased from
29.9% to 62.7% during the same period. In addition, the
prevalence of XDR A. baumannii increased at our hospital
from 3.7% in 2008 to 19.6% in 2009 and to 41.9% in 2010. Few
clinical data are available on XDR A. baumannii from China.
In order to explore the causes for the rapid increase of XDR
A. baumannii and to identify whether a nosocomial dissem-
ination of XDR A. baumanniiwith molecular relatedness was
occurring at our hospital, the clonality of the isolates and the
presence of carbapenemase genes were determined.
Furthermore, the risk factors for hospital-acquired XDR A.
baumannii were analyzed by a caseecontrol study and
antimicrobial treatment options were evaluated.Materials and methods
Hospital setting and bacterial isolates
This study was conducted at the Huashan Hospital, a ter-
tiary care university hospital, in Shanghai, China, which hasapproximately 1300 beds, including 260 neurosurgical beds.
All consecutive and nonduplicate clinical XDR A. baumannii
isolates (n Z 106) were collected at the hospital from
January to December 2010. Rapid species identification was
performed by one-tube multiplex polymerase chain reac-
tion (PCR).7 A. baumannii was identified if two PCR prod-
ucts were yielded: a 425-bp internal control amplicon
corresponding to the recA gene of Acinetobacter spp. and
the 208-bp fragment of the 16Se23S rRNA intergenic spacer
region of A. baumannii. Non-baumannii Acinetobacter iso-
lates, which yielded the 425-bp PCR product alone, were
excluded in this study. Isolates were recovered from the
respiratory tract (n Z 76), drainage fluid (n Z 9), urine
(n Z 6), wound (n Z 6), blood (n Z 5), catheter (n Z 3)
and cerebrospinal fluid (n Z 1).
The criteria set by the National Healthcare Safety
Network were used to determine whether isolation of A.
baumannii indicated colonization or infection.8 Hospital
acquisition was defined as detection of colonization or
infection at least 72 hours after arrival at the medical fa-
cility. XDR strains first isolated from patients admitted to
hospital within 72 hours or patients who had A. baumannii
infections in other hospitals prior to this admission were
defined as imported strains.
Antimicrobial susceptibility testing
The minimal inhibitory concentrations (MICs) of 16 antimi-
crobial agents were measured by agar dilution according to
the recommendations of the Clinical and Laboratory Stan-
dards Institute 2014.9 Tigecycline MICs were determined by
broth microdilution using Food and Drug Administration
clinical MIC breakpoints for Enterobacteriaceae: 2 mg/L
for susceptible and 8 mg/L for resistant. Escherichia coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were
used as reference strains.
CRAB was defined if an A. baumannii isolate was resis-
tant to both imipenem and meropenem. MDR A. baumannii
is defined as acquired nonsusceptibility to at least one
agent in three or more antimicrobial categories. XDR A.
baumannii is defined by nonsusceptible to at least one
agent in all but two or fewer antimicrobial categories (re-
mains susceptible to only 1 or 2 categories).10
Molecular typing
Molecular typing of isolates was performed by enterobac-
terial repetitive intergenic consensus-PCR (ERIC-PCR) and
multilocus sequence typing (MLST). Primer ERIC-2 was used
for amplification. PCR conditions were described previ-
ously.11 The DNA banding patterns were analyzed using
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compared and interpreted according to the number of band
differences.12 MLSTwas carried out as described previously.
In brief, internal fragments of seven housekeeping genes
(gltA, gyrB, gdhB, recA, cpn60, gpi, and rpoD) were PCR
amplified, purified, and sequenced.13 A clonal complex (CC)
comprised a founding sequence type (ST) as a common
ancestor and other closely related STs descended from the
predicted founding genotype, defined by adjoining single
locus variants.
Detection of carbapenemase genes
Genes coding for class A, B, and D carbapenemases were
investigated by PCR. Multiplex PCR was performed with
primers that anneal to blaOxA-23-like, blaOxA-24-like, blaOxA-
51-like, and blaOxA-58-like carbapenemases.
2 The entire
blaOxA-23-like and blaOxA-51-like coding regions were ampli-
fied and sequenced using primer pairs as previously
described.14,15 Metallo-b-lactamase, blaNDM, was detected
with PCR conditions and primers described previously.16 To
detect the presence of blaKPC, blaIMP and blaVIM, the
following primer sets were used: KPC-F, GCTCAGGCGC
AACTGTAAGT and KPC-R, GTCCAGACGGAACGTGGTAT; IMP-
F, GGAATAGAGTGGCTTAATTCTC and IMP-R, GCAGCCAAAC
CACTAWGTTATCT; VIM-F, GCACTTCTCGCGGAGATTG and
VIM-R, ATCGAATGCGCAGCACC. Reaction conditions of PCR
were 94C for 5 minutes and 35 cycles of 94C for 30 sec-
onds, 53C for 30 seconds, and 72C for 30 seconds, fol-
lowed by a final extension at 72C for 5 minutes.
Caseecontrol study and chart review
The case group included patients infected or colonized with
hospital-acquired XDR A. baumannii. The control group
included all patients with hospital-acquired non-XDR A.
baumannii at main campus of Huashan Hospital in 2010
were included. The medical records of patients in the case
and control groups were reviewed in order to extract
epidemiologic data and clinical information. Prior antibiotic
exposures were defined as at least 24 hours of therapy
during the 14 days prior to isolation of the organism for the
A. baumannii-positive patients. Records were examined to
identify isolation of other MDR organisms, such as Pseudo-
monas aeruginosa, vancomycin-resistant Enterococcus spp.
and methicillin-resistant Staphylococcus aureus. In-hospital
mortality was recorded; death was attributed to infection
when it occurred during the acute phase of the infection or
when the patient was still receiving treatment. Time at risk
was defined as length of stay prior to A. baumannii isolation
for A. baumannii-positive patients.
Therapy of XDR A. baumannii infections was also eval-
uated. Response to treatment was defined as normalization
of vital signs and resolution of clinical symptoms associated
with infection (resolution of fever), improvement in arte-
rial blood-gas values, normal blood counts, radiological
improvement, and negative culture from the source related
to infection. Efficacy rates of cefoperazoneesulbactam,
carbapenems, and aminoglycoside alone or combined with
other antibiotics were calculated and compared. The
duration of treatment varied from 5 days to 3 weeks. Theclinical response was evaluated 3 days after initiating
treatment.
The study was approved by the Institutional Review
Board of the Huashan Hospital, Shanghai, China (KY2013-
314 and KY2013-316).Statistical analysis
Continuous variables were presented as mean  standard
deviation, and comparative analysis was conducted using
an independent sample nonparametric test. A Chi-square
test and Fisher’s exact test were used for comparative
analysis of categorical variables, and the odds ratio was
calculated with 95% confidence intervals. To determine
independent risk factors, multivariate analysis was per-
formed using forward stepwise logistic regression with a to
enter equaling 0.05 and a to remove equaling 0.10. Statis-
tical significance was defined as p < 0.05. SPSS 20.0 (SSPS
Inc., Chicago, IL, USA) was used for all analyses.Results
All 106 A. baumannii isolates were resistant to every anti-
microbial agent tested except that 105 strains (99.1%) were
susceptible to colistin, 55 (51.9%) susceptible to tigecycline
and three (2.8%) susceptible to cefoperazoneesulbactam.
One strain had a colistin MIC of 256 mg/L (Table 1).
All strains had more than 10 bands for the ERIC profile.
Twelve distinct clonal types were identified by ERIC-PCR
with clone A1 accounting for 73.6% (78/106; Table 2). Eight
distinct STs were identified by MLST (Fig. 1A). Seven STs of
ST138, ST395, ST75, ST92, ST90, ST118 and ST735 accoun-
ted for 99.1% (105/106) and were clustered into clonal
complex 92. Although ST138 was the most common ST
comprised 30.2% (32/106) in this study, the six STs were
single-locus variants of ST92, different from each other
only in the gpi locus (Table 2). ST92, a globally distributed
type, was the predicted founder of CC92 in A. baumannii
MLST database (Fig. 1B). Only one non-CC92 STs (ST671)
strain identified in the present study fell into distinct
singleton (Table 2). Of 78 ERIC-PCR A1 strains, there were
23 each of ST138 and ST395, 17 ST92, and 15 ST75, all
belonging to CC92.
OXA-type carbapenemase including blaOxA-23 and blaOxA-66
genes were present in all 105 isolates belonging to clonal
complex 92. The presence of blaOxA-23 and blaOxA-69 was
revealed in the strain belonged to ST671. No blaKPC, blaNDM,
blaVIM, blaIMP, blaOxA-24-like and blaOxA-58-like genes were
detected.
Seven outpatients and six inpatients from whom com-
plete data could not be obtained were omitted from further
analysis. Of the remaining 93 cases, 81 (87.1%) were iso-
lated from patients with hospital-acquired infections who
had prolonged hospital stays (average, 68.6 days), and 12
(12.9%) were defined as imported strains. Among 93 pa-
tients, 41 (44.1%) received neurosurgery and 38 (40.9%)
were admitted to the ICU. Seventy-two patients (77.4%)
had a tracheostomy or endotracheal tube, and 51 patients
(55.4%) received mechanical ventilation. The overall in-
hospital mortality was 17.2% (16/93).
Table 1 Antimicrobial susceptibility of 106 extensively drug-resistant Acinetobacter baumannii isolates (mg/L)
Antimicrobial MIC range MIC50 MIC90 Susceptibility
percentage
Piperacillin 128e512 512 512 0
Ceftazidime 32e256 64 256 0
Cefepime 32e256 64 128 0
Piperacillinetazobactam 128e256 256 256 0
Ampicillinesulbactam 32e128 32 64 0
Cefoperazoneesulbactama 16e128 32 64 2.8%
Imipenem 16e256 32 64 0
Meropenem 16e128 16 64 0
Minocycline 8e32 8 16 0
Tigecyclineb 1e16 2 8 51.9%
Ciprofloxacin 8e128 64 64 0
Amikacin 64e256 256 256 0
Trimethoprim
esulfamethoxazole
8e16 16 16 0
Colistin 0.25e256 0.5 0.5 99.1%
Rifampicin 2e16 4 8 dc
Sulbactam 8e256 32 32 dc
a Cefoperazone-sulbactam MICs of 16/8 mg/L, 32/16 mg/L and 64/32 mg/L were interpreted as susceptible, intermediate and
resistant, respectively.
b Tigecycline MICs of 2 mg/L and 8 mg/L were interpreted as susceptible and resistant.
c No Clinical and Laboratory Standards Institute breakpoints.
MIC Z minimal inhibitory concentration.
104 Y. Li et al.Of the 93 patients, 43 were classified as infected and 50
as colonized with XDR A. baumannii. Among the 43 infected
patients, 29 had hospital-acquired pneumonia (including 13
ventilator-associated pneumonia), four each bloodstream
infections and abdominal infections, three urinary tract
infections, two wound infections, and one meningitis. NoTable 2 Multilocus sequence typing (MLST) and enterobacteria
sively drug-resistant Acinetobacter baumannii isolates
MLST type No. of isolates ERIC type
STa gpi allele
75 11 15 A1
75 11 4 G
75 11 2 E
75 11 1 D
92 7 17 A1
92 7 1 H
92 7 1 J
138 50 23 A1
138 50 2 A2
138 50 1 H
138 50 6 K
395 58 23 A1
395 58 1 L
90 62 1 B
90 62 5 F
735 197 1 E
118 3 1 I
671 d 1 C
a All the STs except ST671 belong to CC92, different from each oth
b Genetic relationship was identified by the number(s) of different E
2e3 bands, closely related; 4e6 bands, possibly related; 7 bands, ustatistically significant difference was observed between
infected and colonized patients in terms of clinical char-
acteristics, except that colonized patients had a longer
time at risk (colonized patients, average 43.7 days vs.
infected patients, 15.6 days, p Z 0.04), a longer duration
of hospital stay (average 100.8 vs. 31.0 days, p Z 0.002),l repetitive intergenic consensus (ERIC) typing of 106 exten-
No. of different bands
compared with ERIC A1
Genetic relationship
with ERIC A1b
0 d
2 Closely related
3 Closely related
2 Closely related
0 d
2 Closely related
2 Closely related
0 d
1 Different subtype
2 Closely related
2 Closely related
0 d
4 Possibly related
3 Closely related
3 Closely related
3 Closely related
2 Closely related
7 Unrelated
er only in the gpi locus.
RIC-PCR bands compared with ERIC A1: 1 band, different subtype;
nrelated.
Figure 1. (A) The relatedness of the sequence types (STs) of 106 strains in this study. (B) eBURST population snapshot of clonal
complex 92 (CC92) from the A. baumannii MLST website. eBURST was performed using six as the minimum identical loci for the
definition of CC and three as the minimum single locus variants. The radial diagram reflects the predicted evolutionary descent
from the founder ST. The size of the circle corresponds to the number of isolates belonging to a ST.
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(96.0% vs. 58.1%, p < 0.001; Supplementary Table).
The 13 patients with incomplete clinical data, 12 pa-
tients with imported XDR A. baumannii, and four patients
with hospital stay <48 hours could not be evaluated and
were not included in further analysis. The case group
consisted of 77 patients, and control group with hospital-
acquired non-XDR A. baumannii included 212 patients
(Table 3). There was no difference in the sex and mean
age. The isolates were mostly recovered from the respi-
ratory tract both in the case (71.4%, 55/77) and control
group (70.8%, 150/212). More patients (40.3%) in the case
group were in an ICU at the time of A. baumannii isola-
tion and had more previous hospitalization (72.7%). Thepresence of gastric tube, bladder catheter, intubation or
tracheostomy, intravascular catheter, and history of sur-
gery were also associated with acquisition of XDR A.
baumannii. Patients in the case group were previously
treated with more classes of antibiotics (4.2 classes),
including carbapenems and b-lactam/b-lactamase com-
binations. However, a difference in the underlying dis-
eases was not significant by univariate analysis, including
cardiovascular disease, cerebral vascular accident,
trauma, tumor, and diabetes. Four independent risk
factors were identified in the multivariate analysis:
location in an ICU, recent general anesthesia, number of
previous antibiotic classes administered, and previous
hospitalization (Table 4).
Table 3 Comparison of clinical characteristics between patients with extensively drug-resistant (XDR) and non-XDR Acine-
tobacter baumannii isolates
Clinical characteristics Case (XDR
isolates, n Z 77)
Control (non-XDR
A. baumannii, n Z 212)
p Odds ratio
(95% CI)
Male sex, n (%) 52 (67.5%) 147 (69.3%) 0.769 0.92 (0.53e1.61)
Age, mean y (range) 59.5 (10e93) 62.7 (17e98) 0.140 0.99 (0.98e1.00)
In ICU at the time of isolation, n (%) 31 (40.3%) 24 (11.3%) <0.001 5.28 (2.83e9.84)
Neurosurgery patients, n (%) 29 (37.7%) 73 (34.4%) 0.767 1.08 (0.64e1.84)
Time at risk, mean d (range) 30.0 (4e350) 25.9 (4e613) 0.119 1.00 (1.00e1.01)
Predisposing factors, n (%)
Gastric tube 67 (87.0%) 159 (75.0%) 0.029 2.23 (1.07e4.65)
Proton pump inhibitors 65 (84.4%) 170 (80.2%) 0.415 1.34 (0.66e2.70)
Bladder catheter 62 (80.5%) 138 (65.1%) 0.012 2.22 (1.18e4.16)
Intubation/tracheostomy 58 (75.3%) 109 (51.4%) <0.001 2.88 (1.61e5.17)
Suctioning/bronchoscopy 55 (71.4%) 129 (60.8%) 0.098 1.72 (0.97e3.04)
Intravascular catheter 52 (67.5%) 111 (52.4%) 0.020 1.89 (1.09e3.27)
Surgery 45 (58.4%) 111 (52.4%) 0.033 1.28 (0.76e2.17)
General anesthesia 38 (49.4%) 92 (43.4%) 0.368 1.27 (0.75e2.14)
Glucocorticoid therapy 26 (33.8%) 71 (33.5%) 0.965 1.01 (0.58e1.76)
Previous use of antibiotics, n (%)
Carbapenems 48 (62.3%) 91 (42.9%) 0.003 2.20 (1.29e3.76)
b-lactam/b-lactamase combinations 43 (55.8%) 85 (40.1%) 0.017 1.87 (1.11e3.18)
Fluoroquinolones 24 (31.2%) 51 (24.1%) 0.220 1.42 (0.80e2.53)
Number of previous antibiotic classes used 4.2 (0e14) 2.8 (0e14) <0.001 1.21 (1.10e1.33)
Previous hospitalization within 1 mo, n (%) 56 (72.7%) 113 (53.3%) 0.003 2.34 (1.32e4.13)
Isolation of other MDR bacteria, n (%) 59 (76.6%) 156 (73.6%) 0.601 1.18 (0.64e2.16)
Duration of hospital stay, mean d (range) 67.8 (3e734) 84.4 (4e1613) 0.600 1.00 (1.00e1.00)
Overall in-hospital mortality, n (%) 16 (20.8%) 31 (14.6%) 0.210 1.53 (0.78e2.99)
CI Z confidence interval; ICU Z intensive care unit; MDR Z multidrug-resistant.
106 Y. Li et al.Of 43 XDR A. baumannii infected patients, eight were
treated with intravenous cefoperazoneesulbactam alone or
combined with other antibiotics (except carbapenems),
and were effective in five patients (62.5%). Both cefoper-
azoneesulbactam-susceptible A. baumannii-infected pa-
tients were evaluated as effective (the third
cefoperazoneesulbactam-susceptible isolate was evalu-
ated as colonization). Cefoperazoneesulbactam (2:1) was
given in dosages ranging from 3.0 g 12-hourly to 6-hourly.
Intravenous carbapenems alone or combined with other
antibiotics (except cefoperazoneesulbactam) were used in
19 patients, and were effective in 9 (47.4%) of these pa-
tients as assessed by clinical and laboratory improvement.
The most frequently used carbapenem was meropenem
(16/19), which was given in dosages ranging from 1.0 g
6e12-hourly to 2.0 g 8-hourly. Other carbapenems used
were panipenem and imipenem. Seven patients were given
both carbapenem and cefoperazoneesulbactam (3 wereTable 4 Multivariate analysis of risk factors related to extens
(against non-XDR A. baumannii)
Variables b
In ICU at the time of isolation 1.794
General anesthesia 0.868
Number of previous antibiotic classes used 0.194
Previous hospitalization within 1 mo 0.632
CI Z confidence interval.combined with doxycycline or minocycline), which was
effective in three (42.9%) patients (Table 5).Discussion
The present study revealed that the rapid increase of XDR
A. baumannii at our hospital between January to December
2010, was due to clonal dissemination of closely related
OXA-23-producing organisms. Both ERIC-PCR and MLST
showed that almost all isolates were clonally related and
CC92 was responsible for the spread. On a global scale,
ST92 is the predicted founder of CC92, the largest and most
geographically diverse clonal complex by MLST.17 Our re-
sults revealed that our facility in Shanghai, China is
included in this global epidemic. So far, ST92 isolates have
been reported from Spain, Korea, Hong Kong, Australia and
America according to the A. baumannii MLST web siteively drug-resistant (XDR) Acinetobacter baumannii isolation
Odds ratio (95% CI) p
6.016 (1.10e2.49) <0.001
2.382 (0.24e1.50) 0.007
1.215 (0.08e0.30) <0.001
1.882 (0.01e1.25) 0.045
Table 5 Antimicrobial therapy and treatment efficacy rate of 43 extensively drug-resistant (XDR) Acinetobacter baumannii
infections
Antimicrobial Combined with Total (n) Effective (n) Ineffective (n) Efficacy rate (%)
Carbapenems Alone 12 6 6 50%
Isepamicin 1 1 0 100%
Doxycycline/
minocycline
6 2 4 33.3%
Cefoperazoneesulbactam Alone 4 3 1 75%
Amikacin/isepamicin 2 2 0 100%
Doxycycline/
minocycline
2 0 2 0%
Carbapenems þ Cefoperazone
 sulbactam
Alone 4 2 2 50%
Doxycycline/
minocycline
3 1 2 33.3%
Aminoglycosides Amikacin alone 1 0 1 0%
Isepamicin Doxycycline/
minocycline
1 1 0 100%
No antimicrobial treatment 7 2 5 28.6%
Clonal dissemination of XDR A. baumannii 107(http://pubmlst.org/abaumannii/). We also observed that,
in our highly clonal isolate collection, ERIC-PCR was able to
cluster CC92 isolates accurately. ERIC-PCR is a very inex-
pensive typing method compared with MLST or even pulsed-
field gel electrophoresis. Our findings suggest that ERIC-
PCR, complemented by selective use of MLST, may be a
cost-efficient approach in addressing hospital epidemiology
of A. baumannii.
Carbapenemase-producing strains of A. baumannii have
been involved in outbreaks in Europe, Asia, and both North
and South America.2,18e20 The carbapenemases produced
by such strains are mostly class D oxacillinases,2,18,20
although metalloenzymes of the IMP, VIM, and NDM fam-
ilies have also been detected in some well-defined
geographical regions.2 All XDR isolates in our clonal
dissemination harbored blaOxA-23 and blaOxA-66 (but one
blaOxA-69) genes, consistent with previous reports.
2,18,20
Although several risk factors have been previously
associated with MDR/CRAB colonization and infection,3,21,22
to date there has been little research on the risk factors for
XDR A. baumannii. One study from Taiwan identified prior
use of imipenem, meropenem, piperacillin/tazobactam, or
fourth-generation cephalosporins and >30 days bed-ridden
as independent risk factors for XDR A. baumannii hospital-
acquired infection.23 We identified four risk factors
for isolation of XDR A. baumannii in our retrospective
caseecontrol study. Among them, general anesthesia
has not been reported as a risk factor in previous studies. In
our study, 41 (44.1%) patients were neurosurgery patients,
and most of them had received general anesthesia
during surgery. General anesthesia is known to increase the
risk of pulmonary infections in general.24 The risk related
to the number of antibiotics presumably reflects easier
selection of resistant strains, consistent with previous
studies.3,21,25,26
ICU location was associated with XDR A. baumannii
colonization and infection in this study, which was consis-
tent with previous reports.3,21,22 Previous hospitalization
increased the probability of XDR A. baumannii isolation.
Huashan Hospital is a leading referral hospital for easternChina, and so collects patients and their resistant flora from
a broad population, which probably contributed in making
this a significant risk factor.
The neurosurgery department utilizes 260 of the 1326
beds (19.6%) at our hospital. Our results indicate that
neurosurgery patients accounted for 44.1% of those
with XDR A. baumannii. However, in our caseecontrol study,
such patients showed no significant difference between the
case and control group, implying that both XDR and non-XDR
A. baumannii were common in neurosurgical patient.
Cefoperazoneesulbactam is a commonly used antimi-
crobial for the treatment of CRAB or XDR A. baumannii
infections in China because of the lack of polymyxins
and tigecycline (prior to 2011). National bacterial surveil-
lance project CHINET showed that cefoperazone-sulbactam
and minocycline had the lowest resistance rates of
both 31% (in addition, 25% were intermediate for cefoper-
azoneesulbactam) followed by ampicillinesulbactam (53%
resistance) for 5523 strains of Acinetobacter spp., of which
90% were A. baumannii in 2010.7 In our retrospective
analysis, eight of 43 XDR A. baumannii patients were
treated with cefoperazoneesulbactam alone or in combi-
nation with a resulting efficacy rate of 62.5%, which was
higher than that of carbapenems alone or in combination
(47.4%). This study indicated that high-dose intravenous
cefoperazoneesulbactam and carbapenem alone or com-
bined with other antibiotics was effective in some patients
and could be considered choices for treatment when other
options are not available.
In summary, OXA-23-producing XDR A. baumannii
disseminated clonally at our referral hospital. Further
investigation revealed the role of neurosurgery and general
anesthesia in the spread XDR A. baumannii. Infection con-
trol measures will need to take into account the risk factors
for this emerging problem.Conflicts of interest
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